08:10 AM EDT, 09/29/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) shares fell 87% pre-bell Monday after Bloomberg reported that late-stage trial data for the company's experimental skin disease drug, sonelokimab, failed to demonstrate superiority over a rival treatment from UCB.

Maris-Tech ( MTEK ) stock was down 43% after the company reported late Friday weaker financial results for the six months ended June 30 versus a year earlier.

Precipio ( PRPO ) shares were 15% lower, adding to Friday's loss.